Skip to main content
Premium Trial:

Request an Annual Quote

EU Consortium Gets €14M to Personalize Treatment of Inflammatory Diseases

NEW YORK (GenomeWeb) – A new international consortium called SYSCID (A systems medicine approach to chronic inflammatory disease) has received €14.4 million ($15.3 million) to support a five-year research project with the goal of developing personalized medicine approaches for inflammatory bowel disease, rheumatoid arthritis, and systemic lupus erythematosus.

Coordinated by Kiel University in Germany, the effort involves academic and industry partners from nine different countries.

Philip Rosenstiel, scientific coordinator of the SYSCID consortium, said in a statement that the effort will investigating a variety of biomarkers "from the epigenome to the microbiome," as well as tools like single-cell analysis. Using build data from previous and ongoing research activities like the International Human Epigenome Consortium, SYSCID hopes to better understand patient response and non-response to current treatment regimens.

"With many new targeted therapies coming to the market, we need the right therapy at the right time," Rosenstiel added.

The project will also seek to develop new therapeutic strategies that address root causes of disease, such as epigenetics, rather than just their immune effects and symptoms.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.